ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft
Investment analysts at Deutsche Bank Aktiengesellschaft assumed coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage set a “hold” rating and a $22.00 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would suggest a potential […]
![ACADIA Pharmaceuticals (NASDAQ:ACAD) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/acadia-pharmaceuticals-inc-logo-1200x675.jpg?v=20221122152651&w=240&h=240&zc=2)